A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
Based on the bill's title, this legislation would amend the Public Health Service Act to streamline the regulatory review process for biosimilar biological products. Biosimilars are drugs designed to be highly similar to existing FDA-approved biological medications. The bill aims to expedite or simplify how the FDA evaluates and approves these products. Without access to the full text, the specific mechanisms and scope of streamlining cannot be determined.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.